Cema-cel Consolidation in MRD+ First-Line LBCL

Market
0.0%
100%75%50%25%0%Apr 12 • YES 38.0%Apr 12
Trade

Will the results be positive?

Paper Trading
DetailsModel PositionsModel SnapshotsOracle
Details
Primary Completion
12/1/27
Study Completion
12/1/32
Company
Allogene Therapeutics
Ticker
ALLO
Type
Phase 2
Trial Status
Recruiting
Trial Size
250
Volume
$193K
NCT
NCT06500273
Drug Description
Randomized, open-label Phase 2 study in adults with large B-cell lymphoma who completed first-line therapy, achieved CR or PR suitable for observation, and are MRD-positive by the Foresight CLARITY™ IUO test. Participants are randomized 1:1 to consolidation with cemacabtagene ansegedleucel following fludarabine/cyclophosphamide lymphodepletion or to standard-of-care observation, with event-free survival as the primary endpoint.